Non-coding RNA-directed therapeutics in lung cancer: Delivery technologies and clinical applications

Ahmed A H Abdellatif; Giulia Scagnetti; Mahmoud A Younis; Abdellatif Bouazzaoui; Hesham M Tawfeek; Basmah N Aldosari; Alanood S Almurshedi; Mansour Alsharidah; Osamah Al Rugaie; Michael P A Davies; Triantafillos Liloglou; Kehinde Ross; Imran Saleem

doi:10.1016/j.colsurfb.2023.113466

Non-coding RNA-directed therapeutics in lung cancer: Delivery technologies and clinical applications

Colloids Surf B Biointerfaces. 2023 Sep:229:113466. doi: 10.1016/j.colsurfb.2023.113466. Epub 2023 Jul 18.

Affiliations

¹ Department of Pharmaceutics, College of Pharmacy, Qassim University, Al Qassim 51452, Saudi Arabia; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt. Electronic address: a.abdellatif@qu.edu.sa.
² School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, James Parsons Building, Liverpool L3 3AF, UK.
³ Department of Industrial Pharmacy, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
⁴ Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia; Science and Technology Unit, Umm Al-Qura University, Makkah 21955, Saudi Arabia; Medical Clinic, Hematology/Oncology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg 93053, Germany.
⁵ Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
⁶ Department of Physiology, College of Medicine, Qassim University, Buraydah 51452, Saudi Arabia.
⁷ Department of Basic Medical Sciences, College of Medicine and Medical Sciences, Qassim University, P.O. Box 991, Unaizah, Al Qassim 51911, Saudi Arabia.
⁸ Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular & Integrative Biology, The University of Liverpool, UK.
⁹ Faculty of Health, Social Care & Medicine, Edge Hill University, Lancashire, UK.
¹⁰ School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, James Parsons Building, Liverpool L3 3AF, UK; Institute for Health Research, Liverpool John Moores University, Liverpool L3 3AF, UK.
¹¹ School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, James Parsons Building, Liverpool L3 3AF, UK; Institute for Health Research, Liverpool John Moores University, Liverpool L3 3AF, UK. Electronic address: i.saleem@ljmu.ac.uk.

PMID: 37515959
DOI: 10.1016/j.colsurfb.2023.113466

Abstract

Lung cancer is one of the most aggressive and deadliest health threats. There has been an increasing interest in non-coding RNA (ncRNA) recently, especially in the areas of carcinogenesis and tumour progression. However, ncRNA-directed therapies are still encountering obstacles on their way to the clinic. In the present article, we provide an overview on the potential of targeting ncRNA in the treatment of lung cancer. Then, we discuss the delivery challenges and recent approaches enabling the delivery of ncRNA-directed therapies to the lung cancer cells, where we illuminate some advanced technologies including chemically-modified oligonucleotides, nuclear targeting, and three-dimensional in vitro models. Furthermore, advanced non-viral delivery systems recruiting nanoparticles, biomimetic delivery systems, and extracellular vesicles are also highlighted. Lastly, the challenges limiting the clinical trials on the therapeutic targeting of ncRNAs in lung cancer and future directions to tackle them are explored.

Keywords: Lung cancer; Nanocarriers; Non-coding RNA; Oligonucleotides.

Publication types

Review

MeSH terms

Carcinogenesis
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / therapy
Molecular Targeted Therapy / methods
RNA, Untranslated* / genetics
RNA, Untranslated* / therapeutic use

Substances

RNA, Untranslated